<DOC>
	<DOC>NCT00825305</DOC>
	<brief_summary>This study investigates the safety and immunogenicity (non-inferiority) of a Purified Chick Embryo Cell Vaccine (PCECV) administered in two different schedules (conventional versus abbreviated schedule) in healthy adults 18 to 50 years of age in China</brief_summary>
	<brief_title>Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male and female subjects 1850 years of age who: are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator; volunteer for the simulated postexposure vaccination courses and blood draws; have given a written informed consent; informed consent must be obtained for all the subjects before enrolment in the study; are available for all the visits scheduled in the study. Subjects with the below criteria were excluded: pregnancy or unwillingness to practice acceptable contraception during participation in the study; a history of rabies immunization; a significant acute or chronic infectious disease that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment; fever ≥ 38.0°C (axillary) or/and significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrolment; treatment with corticosteroids, immunosuppressive or antimalaria drugs during the two month period before enrolment; administration of any vaccine within the past 14 days before enrolment; known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder; history of allergy to egg protein; known hypersensitivity to neomycin, tetracycline, amphotericinB, or any other vaccine component; treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months; mental condition rendering the subject unable to understand the nature, scope and consequences of the study; participation in any other investigational trial within the past 3 months before enrolment; planned surgery during the study period; intention to leave the area of the study site before the end of study period; any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objective.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>vaccine</keyword>
	<keyword>prevention</keyword>
	<keyword>rabies</keyword>
	<keyword>Rabies disease</keyword>
</DOC>